 Free access

2,109 | 16

Views | CrossRef citations to date | Altmetric


[Listen](#)

Research Article

# Synthesis, hydrolysis studies and pharmacodynamic profiles of amide prodrugs of dexibuprofen with amino acids

Arun Rasheed , C. K. Ashok Kumar & Ashutosh Mishra

Pages 688-695 | Received 28 Mar 2010, Accepted 09 Dec 2010, Published online: 21 Jan 2011

 Cite this article  <https://doi.org/10.3109/14756366.2010.548327> Full Article Figures & data References Citations Metrics Reprints & Permissions View PDF

## Abstract

The present investigation deals with the synthesis of novel prodrugs of dexibuprofen with amino acids with an aim to achieve potent anti-inflammatory activity and less gastrointestinal toxicity. Structures of synthesized compounds were confirmed by spectral and elemental analyses. In vitro hydrolytic studies in simulated intestinal fluid, 80% plasma and rat faecal matter showed satisfactory release of dexibuprofen due to enzymatic activity.

### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All 

Essential Only

Settings

## Introduction

Dexibuprofen (Dex), a novel non-steroidal anti-inflammatory drug (NSAID), is a single and pharmacologically effective enantiomer of racemic ibuprofen. Racibuprofen and dexibuprofen differ in their physicochemical properties, pharmacological profiles and metabolic activities<sup>1</sup>. The efficacy of dexibuprofen was found to be same as that of other NSAIDs, such as diclofenac, naproxen and celecoxib. Generally, the NSAIDs are associated with various gastrointestinal (GI) side effects like stomach ulceration, bleeding and perforation due to the presence of its acidic group. The GI toxicity is produced either by direct contact mechanism or by generalized systemic action, which occur after absorption. To overcome the GI side effects, prodrugs of NSAIDs can be developed by hiding its acidic group through conjugation with amino acids. Many amino acids possess site specificity, marked anti-inflammatory activity and exhibit profound healing effect on gastric toxicity<sup>2</sup>. During conjugation, the NSAIDs having free carboxylic group can be derivitized into corresponding amides of amino acid, and it results in altering the physical properties of parent drug with one or more of hydrolase enzymes serving as the in vivo reconversion sites. The new prodrugs were expected to have better lipophilicity, reduced gastric irritancy, improved therapeutic index through the prevention of GI irritation and bleeding, improved anti-inflammatory activity, reduced GI erosive properties and synergistic analgesic effect than the parent drug<sup>3,4</sup>.

The synthesis of prodrugs of ketoprofen, diclofenac, flubiprofen, naproxen, ibuprofen, etc., with various amino acids via masking the carboxylic acid group to form ethyl ester, methyl ester and glycolamide ester prodrug<sup>5-7</sup> were carried out successfully so far. The

### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings

# Materials and methods

## Materials

The amino acids L-tryptophan, L-phenylalanine, glycine and L-tyrosine were obtained from M/s Hi-Media Ltd., India, and drug dexibuprofen was obtained as a gift sample from Alkem Laboratories, India. Other reagents and solvents were of analytical grade. The melting points were recorded using melting point determination apparatus by Sigma Instrument, India, and are uncorrected. The elemental analysis was performed using Carlo-Erba Model 1108 Analyzer (Italy).  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra were recorded in dimethylsulphoxide (DMSO) on NMR spectrophotometer (Bruker DRX 300, USA). Chemical shifts are expressed as  $\delta$  (ppm) values. IR spectra were recorded using IR spectrophotometer (Shimadzu FTIR-8201PC (Kyoto, Japan)) in KBr phase and mass spectra were recorded on mass spectrophotometer (Jeol SX-102 (FAB), Japan). The hydrolysis data and drug content determination were performed by ELICO Double Beam UV-VIS Spectrophotometers (Hyderabad, India).

## Synthesis of amide prodrugs of dexibuprofen

Dexibuprofen is 2-[4-(2-methyl propyl) phenyl] propanoic acid and the synthesis of its amide prodrugs was carried out by Schotten Baumann technique<sup>8</sup> as explained below. The purity of the compounds was checked by thin-layer chromatography on pre-coated silica GF<sub>252</sub> plates using iodine vapour as a detecting agent. The structures of all the synthesized prodrugs were confirmed by elemental analysis and spectral analysis such as IR,  $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR and mass spectroscopy.

### Step 1: Synthesis of dexibuprofen acid chloride

Dex (1) of 10.31 g (0.05 mol L<sup>-1</sup>) was dissolved in minimum amount of chloroform and freshly distilled pyridine (10 mL) was added. The mixture was stirred at room temperature for 15 min. The mixture was then cooled to 0°C and freshly distilled thionyl chloride (10 mL) was added. The mixture was stirred at 0°C for 15 min and then at room temperature for 1 h. The mixture was then poured into ice water and the white precipitate was washed with water. The white solid was dried under vacuum and the white solid was obtained. The mixture was then poured into ice water and the white precipitate was washed with water. The white solid was dried under vacuum and the white solid was obtained.

#### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings



mixture was refluxed for 6–8 h at 60–70°C with continuous stirring on magnetic stirrer. Excess thionyl chloride and solvent was removed under reduced pressure giving crude tryptophan methyl ester hydrochloride. It was treated with 20 mL portion of cold ether at 0°C. The resulting solid product was collected and dried under vacuum. It was recrystallized from hot methanol by slow addition of 15–20 mL ether followed by cooling at 0°C. The crystals were collected next day and washed twice with ether: methanol mixture at 5:1 ratio followed by pure ether and dried under vacuum to give pure tryptophan methyl ester hydrochloride (2a). The same procedure was followed to synthesize phenylalanine methyl ester hydrochloride, glycine methyl ester hydrochloride and tyrosine methyl ester hydrochloride.

### Step 3: Synthesis of prodrugs of dexibuprofen with methyl esters of L-tryptophan, L-phenylalanine, glycine and L-tyrosine

Ice cold, aqueous sodium hydroxide solution (5 %) was taken in 250 mL beaker and 12.6 g ( $0.05 \text{ mol L}^{-1}$ ) of methyl ester of tryptophan hydrochloride was added to it. The reaction mixture was mechanically stirred for 30 min at room temperature, after which the beaker was transferred to an ice bath kept on the mechanical stirrer, maintaining the temperature at 10°C. To this, 22.3 g ( $0.01 \text{ mol L}^{-1}$ ) of dex acid chloride was added in small portions with continuous stirring for 7–8 h. The solid that separated out was filtered off. The crude prodrug was recrystallized from methanol. The same procedure was followed for L-phenylalanine, glycine and L-tyrosine. The schematic representation of synthesis of tryptophan-conjugated dexibuprofen (Dex 1), phenylalanine-conjugated dexibuprofen (Dex 2), glycine-conjugated dexibuprofen (Dex 3) and tyrosine-conjugated dexibuprofen (Dex 4) are shown in [Scheme 1](#).

Scheme 1. Synthetic protocol of amide prodrugs of dexibuprofen.






#### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings

**Step I: Synthesis of dexibuprofen acid chloride****Step II: Synthesis of methyl ester of L-tryptophan****Step III: Synthesis of prodrug: Conjugation of dexibuprofen acid chloride with methyl ester of L- tryptophan**
[Display full size](#)

## Spectral analysis

The spectral data obtained for Dex 1, Dex 2, Dex 3 and Dex 4 are given as follows.

Dex 1: S(+) Methyl 3-(1H-indol-3-yl)-2-(2-(4-isobutylphenyl)propanamido)propanoate–

UV Spectra ( $\lambda_{\text{max}}$ ) in simulated gastric fluid (SGF) 205 nm, in simulated intestinal fluid (SIF) 225 nm, in 80% human plasma 218 nm; IR (KBr,  $\text{cm}^{-1}$ ) 3290 (NH str. of amide), 3075 (aromatic CH str.), 1677 ( $\text{C}=\text{O}$  str. of ester), 1570 ( $\text{C}=\text{N}$ ), 1292 (CO str. of ester);  $^1\text{H}$  NMR ( $\delta$  ppm) ( $\text{DMSO}-d_6$ ) 1.48 (d,  $J = 7.1$  Hz, 3H,  $\text{CH}_3$ ), 1.52 (d,  $J = 6.8$  Hz, 1H, CH), 3.72 (d,  $J = 7.1$  Hz, 2H,  $\text{CH}_2$ ), 7.18 (m, 5H, indol ring), 7.20 (m, 4H, aromatic ring), 9.77 (s, 1H, NH), 2.38, 3.82, 4.35, 4.72, 129.2, 157.0, 167.7, 170.0, 172.5, 175.0, 177.5, 180.0, 182.5, 185.0, 187.5, 190.0, 192.5, 195.0, 197.5, 200.0, 202.5, 205.0, 207.5, 210.0, 212.5, 215.0, 217.5, 220.0, 222.5, 225.0, 227.5, 230.0, 232.5, 235.0, 237.5, 240.0, 242.5, 245.0, 247.5, 250.0, 252.5, 255.0, 257.5, 260.0, 262.5, 265.0, 267.5, 270.0, 272.5, 275.0, 277.5, 280.0, 282.5, 285.0, 287.5, 290.0, 292.5, 295.0, 297.5, 300.0, 302.5, 305.0, 307.5, 310.0, 312.5, 315.0, 317.5, 320.0, 322.5, 325.0, 327.5, 330.0, 332.5, 335.0, 337.5, 340.0, 342.5, 345.0, 347.5, 350.0, 352.5, 355.0, 357.5, 360.0, 362.5, 365.0, 367.5, 370.0, 372.5, 375.0, 377.5, 380.0, 382.5, 385.0, 387.5, 390.0, 392.5, 395.0, 397.5, 400.0, 402.5, 405.0, 407.5, 410.0, 412.5, 415.0, 417.5, 420.0, 422.5, 425.0, 427.5, 430.0, 432.5, 435.0, 437.5, 440.0, 442.5, 445.0, 447.5, 450.0, 452.5, 455.0, 457.5, 460.0, 462.5, 465.0, 467.5, 470.0, 472.5, 475.0, 477.5, 480.0, 482.5, 485.0, 487.5, 490.0, 492.5, 495.0, 497.5, 500.0, 502.5, 505.0, 507.5, 510.0, 512.5, 515.0, 517.5, 520.0, 522.5, 525.0, 527.5, 530.0, 532.5, 535.0, 537.5, 540.0, 542.5, 545.0, 547.5, 550.0, 552.5, 555.0, 557.5, 560.0, 562.5, 565.0, 567.5, 570.0, 572.5, 575.0, 577.5, 580.0, 582.5, 585.0, 587.5, 590.0, 592.5, 595.0, 597.5, 600.0, 602.5, 605.0, 607.5, 610.0, 612.5, 615.0, 617.5, 620.0, 622.5, 625.0, 627.5, 630.0, 632.5, 635.0, 637.5, 640.0, 642.5, 645.0, 647.5, 650.0, 652.5, 655.0, 657.5, 660.0, 662.5, 665.0, 667.5, 670.0, 672.5, 675.0, 677.5, 680.0, 682.5, 685.0, 687.5, 690.0, 692.5, 695.0, 697.5, 700.0, 702.5, 705.0, 707.5, 710.0, 712.5, 715.0, 717.5, 720.0, 722.5, 725.0, 727.5, 730.0, 732.5, 735.0, 737.5, 740.0, 742.5, 745.0, 747.5, 750.0, 752.5, 755.0, 757.5, 760.0, 762.5, 765.0, 767.5, 770.0, 772.5, 775.0, 777.5, 780.0, 782.5, 785.0, 787.5, 790.0, 792.5, 795.0, 797.5, 800.0, 802.5, 805.0, 807.5, 810.0, 812.5, 815.0, 817.5, 820.0, 822.5, 825.0, 827.5, 830.0, 832.5, 835.0, 837.5, 840.0, 842.5, 845.0, 847.5, 850.0, 852.5, 855.0, 857.5, 860.0, 862.5, 865.0, 867.5, 870.0, 872.5, 875.0, 877.5, 880.0, 882.5, 885.0, 887.5, 890.0, 892.5, 895.0, 897.5, 900.0, 902.5, 905.0, 907.5, 910.0, 912.5, 915.0, 917.5, 920.0, 922.5, 925.0, 927.5, 930.0, 932.5, 935.0, 937.5, 940.0, 942.5, 945.0, 947.5, 950.0, 952.5, 955.0, 957.5, 960.0, 962.5, 965.0, 967.5, 970.0, 972.5, 975.0, 977.5, 980.0, 982.5, 985.0, 987.5, 990.0, 992.5, 995.0, 997.5, 1000.0, 1002.5, 1005.0, 1007.5, 1010.0, 1012.5, 1015.0, 1017.5, 1020.0, 1022.5, 1025.0, 1027.5, 1030.0, 1032.5, 1035.0, 1037.5, 1040.0, 1042.5, 1045.0, 1047.5, 1050.0, 1052.5, 1055.0, 1057.5, 1060.0, 1062.5, 1065.0, 1067.5, 1070.0, 1072.5, 1075.0, 1077.5, 1080.0, 1082.5, 1085.0, 1087.5, 1090.0, 1092.5, 1095.0, 1097.5, 1100.0, 1102.5, 1105.0, 1107.5, 1110.0, 1112.5, 1115.0, 1117.5, 1120.0, 1122.5, 1125.0, 1127.5, 1130.0, 1132.5, 1135.0, 1137.5, 1140.0, 1142.5, 1145.0, 1147.5, 1150.0, 1152.5, 1155.0, 1157.5, 1160.0, 1162.5, 1165.0, 1167.5, 1170.0, 1172.5, 1175.0, 1177.5, 1180.0, 1182.5, 1185.0, 1187.5, 1190.0, 1192.5, 1195.0, 1197.5, 1200.0, 1202.5, 1205.0, 1207.5, 1210.0, 1212.5, 1215.0, 1217.5, 1220.0, 1222.5, 1225.0, 1227.5, 1230.0, 1232.5, 1235.0, 1237.5, 1240.0, 1242.5, 1245.0, 1247.5, 1250.0, 1252.5, 1255.0, 1257.5, 1260.0, 1262.5, 1265.0, 1267.5, 1270.0, 1272.5, 1275.0, 1277.5, 1280.0, 1282.5, 1285.0, 1287.5, 1290.0, 1292.5, 1295.0, 1297.5, 1300.0, 1302.5, 1305.0, 1307.5, 1310.0, 1312.5, 1315.0, 1317.5, 1320.0, 1322.5, 1325.0, 1327.5, 1330.0, 1332.5, 1335.0, 1337.5, 1340.0, 1342.5, 1345.0, 1347.5, 1350.0, 1352.5, 1355.0, 1357.5, 1360.0, 1362.5, 1365.0, 1367.5, 1370.0, 1372.5, 1375.0, 1377.5, 1380.0, 1382.5, 1385.0, 1387.5, 1390.0, 1392.5, 1395.0, 1397.5, 1400.0, 1402.5, 1405.0, 1407.5, 1410.0, 1412.5, 1415.0, 1417.5, 1420.0, 1422.5, 1425.0, 1427.5, 1430.0, 1432.5, 1435.0, 1437.5, 1440.0, 1442.5, 1445.0, 1447.5, 1450.0, 1452.5, 1455.0, 1457.5, 1460.0, 1462.5, 1465.0, 1467.5, 1470.0, 1472.5, 1475.0, 1477.5, 1480.0, 1482.5, 1485.0, 1487.5, 1490.0, 1492.5, 1495.0, 1497.5, 1500.0, 1502.5, 1505.0, 1507.5, 1510.0, 1512.5, 1515.0, 1517.5, 1520.0, 1522.5, 1525.0, 1527.5, 1530.0, 1532.5, 1535.0, 1537.5, 1540.0, 1542.5, 1545.0, 1547.5, 1550.0, 1552.5, 1555.0, 1557.5, 1560.0, 1562.5, 1565.0, 1567.5, 1570.0, 1572.5, 1575.0, 1577.5, 1580.0, 1582.5, 1585.0, 1587.5, 1590.0, 1592.5, 1595.0, 1597.5, 1600.0, 1602.5, 1605.0, 1607.5, 1610.0, 1612.5, 1615.0, 1617.5, 1620.0, 1622.5, 1625.0, 1627.5, 1630.0, 1632.5, 1635.0, 1637.5, 1640.0, 1642.5, 1645.0, 1647.5, 1650.0, 1652.5, 1655.0, 1657.5, 1660.0, 1662.5, 1665.0, 1667.5, 1670.0, 1672.5, 1675.0, 1677.5, 1680.0, 1682.5, 1685.0, 1687.5, 1690.0, 1692.5, 1695.0, 1697.5, 1700.0, 1702.5, 1705.0, 1707.5, 1710.0, 1712.5, 1715.0, 1717.5, 1720.0, 1722.5, 1725.0, 1727.5, 1730.0, 1732.5, 1735.0, 1737.5, 1740.0, 1742.5, 1745.0, 1747.5, 1750.0, 1752.5, 1755.0, 1757.5, 1760.0, 1762.5, 1765.0, 1767.5, 1770.0, 1772.5, 1775.0, 1777.5, 1780.0, 1782.5, 1785.0, 1787.5, 1790.0, 1792.5, 1795.0, 1797.5, 1800.0, 1802.5, 1805.0, 1807.5, 1810.0, 1812.5, 1815.0, 1817.5, 1820.0, 1822.5, 1825.0, 1827.5, 1830.0, 1832.5, 1835.0, 1837.5, 1840.0, 1842.5, 1845.0, 1847.5, 1850.0, 1852.5, 1855.0, 1857.5, 1860.0, 1862.5, 1865.0, 1867.5, 1870.0, 1872.5, 1875.0, 1877.5, 1880.0, 1882.5, 1885.0, 1887.5, 1890.0, 1892.5, 1895.0, 1897.5, 1900.0, 1902.5, 1905.0, 1907.5, 1910.0, 1912.5, 1915.0, 1917.5, 1920.0, 1922.5, 1925.0, 1927.5, 1930.0, 1932.5, 1935.0, 1937.5, 1940.0, 1942.5, 1945.0, 1947.5, 1950.0, 1952.5, 1955.0, 1957.5, 1960.0, 1962.5, 1965.0, 1967.5, 1970.0, 1972.5, 1975.0, 1977.5, 1980.0, 1982.5, 1985.0, 1987.5, 1990.0, 1992.5, 1995.0, 1997.5, 2000.0, 2002.5, 2005.0, 2007.5, 2010.0, 2012.5, 2015.0, 2017.5, 2020.0, 2022.5, 2025.0, 2027.5, 2030.0, 2032.5, 2035.0, 2037.5, 2040.0, 2042.5, 2045.0, 2047.5, 2050.0, 2052.5, 2055.0, 2057.5, 2060.0, 2062.5, 2065.0, 2067.5, 2070.0, 2072.5, 2075.0, 2077.5, 2080.0, 2082.5, 2085.0, 2087.5, 2090.0, 2092.5, 2095.0, 2097.5, 2100.0, 2102.5, 2105.0, 2107.5, 2110.0, 2112.5, 2115.0, 2117.5, 2120.0, 2122.5, 2125.0, 2127.5, 2130.0, 2132.5, 2135.0, 2137.5, 2140.0, 2142.5, 2145.0, 2147.5, 2150.0, 2152.5, 2155.0, 2157.5, 2160.0, 2162.5, 2165.0, 2167.5, 2170.0, 2172.5, 2175.0, 2177.5, 2180.0, 2182.5, 2185.0, 2187.5, 2190.0, 2192.5, 2195.0, 2197.5, 2200.0, 2202.5, 2205.0, 2207.5, 2210.0, 2212.5, 2215.0, 2217.5, 2220.0, 2222.5, 2225.0, 2227.5, 2230.0, 2232.5, 2235.0, 2237.5, 2240.0, 2242.5, 2245.0, 2247.5, 2250.0, 2252.5, 2255.0, 2257.5, 2260.0, 2262.5, 2265.0, 2267.5, 2270.0, 2272.5, 2275.0, 2277.5, 2280.0, 2282.5, 2285.0, 2287.5, 2290.0, 2292.5, 2295.0, 2297.5, 2300.0, 2302.5, 2305.0, 2307.5, 2310.0, 2312.5, 2315.0, 2317.5, 2320.0, 2322.5, 2325.0, 2327.5, 2330.0, 2332.5, 2335.0, 2337.5, 2340.0, 2342.5, 2345.0, 2347.5, 2350.0, 2352.5, 2355.0, 2357.5, 2360.0, 2362.5, 2365.0, 2367.5, 2370.0, 2372.5, 2375.0, 2377.5, 2380.0, 2382.5, 2385.0, 2387.5, 2390.0, 2392.5, 2395.0, 2397.5, 2400.0, 2402.5, 2405.0, 2407.5, 2410.0, 2412.5, 2415.0, 2417.5, 2420.0, 2422.5, 2425.0, 2427.5, 2430.0, 2432.5, 2435.0, 2437.5, 2440.0, 2442.5, 2445.0, 2447.5, 2450.0, 2452.5, 2455.0, 2457.5, 2460.0, 2462.5, 2465.0, 2467.5, 2470.0, 2472.5, 2475.0, 2477.5, 2480.0, 2482.5, 2485.0, 2487.5, 2490.0, 2492.5, 2495.0, 2497.5, 2500.0, 2502.5, 2505.0, 2507.5, 2510.0, 2512.5, 2515.0, 2517.5, 2520.0, 2522.5, 2525.0, 2527.5, 2530.0, 2532.5, 2535.0, 2537.5, 2540.0, 2542.5, 2545.0, 2547.5, 2550.0, 2552.5, 2555.0, 2557.5, 2560.0, 2562.5, 2565.0, 2567.5, 2570.0, 2572.5, 2575.0, 2577.5, 2580.0, 2582.5, 2585.0, 2587.5, 2590.0, 2592.5, 2595.0, 2597.5, 2600.0, 2602.5, 2605.0, 2607.5, 2610.0, 2612.5, 2615.0, 2617.5, 2620.0, 2622.5, 2625.0, 2627.5, 2630.0, 2632.5, 2635.0, 2637.5, 2640.0, 2642.5, 2645.0, 2647.5, 2650.0, 2652.5, 2655.0, 2657.5, 2660.0, 2662.5, 2665.0, 2667.5, 2670.0, 2672.5, 2675.0, 2677.5, 2680.0, 2682.5, 2685.0, 2687.5, 2690.0, 2692.5, 2695.0, 2697.5, 2700.0, 2702.5, 2705.0, 2707.5, 2710.0, 2712.5, 2715.0, 2717.5, 2720.0, 2722.5, 2725.0, 2727.5, 2730.0, 2732.5, 2735.0, 2737.5, 2740.0, 2742.5, 2745.0, 2747.5, 2750.0, 2752.5, 2755.0, 2757.5, 2760.0, 2762.5, 2765.0, 2767.5, 2770.0, 2772.5, 2775.0, 2777.5, 2780.0, 2782.5, 2785.0, 2787.5, 2790.0, 2792.5, 2795.0, 2797.5, 2800.0, 2802.5, 2805.0, 2807.5, 2810.0, 2812.5, 2815.0, 2817.5, 2820.0, 2822.5, 2825.0, 2827.5, 2830.0, 2832.5, 2835.0, 2837.5, 2840.0, 2842.5, 2845.0, 2847.5, 2850.0, 2852.5, 2855.0, 2857.5, 2860.0, 2862.5, 2865.0, 2867.5, 2870.0, 2872.5, 2875.0, 2877.5, 2880.0, 2882.5, 2885.0, 2887.5, 2890.0, 2892.5, 2895.0, 2897.5, 2900.0, 2902.5, 2905.0, 2907.5, 2910.0, 2912.5, 2915.0, 2917.5, 2920.0, 2922.5, 2925.0, 2927.5, 2930.0, 2932.5, 2935.0, 2937.5, 2940.0, 2942.5, 2945.0, 2947.5, 2950.0, 2952.5, 2955.0, 2957.5, 2960.0, 2962.5, 2965.0, 2967.5, 2970.0, 2972.5, 2975.0, 2977.5, 2980.0, 2982.5, 2985.0, 2987.5, 2990.0, 2992.5, 2995.0, 2997.5, 3000.0, 3002.5, 3005.0, 3007.5, 3010.0, 3012.5, 3015.0, 3017.5, 3020.0, 3022.5, 3025.0, 3027.5, 3030.0, 3032.5, 3035.0, 3037.5, 3040.0, 3042.5, 3045.0, 3047.5, 3050.0, 3052.5, 3055.0, 3057.5, 3060.0, 3062.5, 3065.0, 3067.5, 3070.0, 3072.5, 3075.0, 3077.5, 3080.0, 3082.5, 3085.0, 3087.5, 3090.0, 3092.5, 3095.0, 3097.5, 3100.0, 3102.5, 3105.0, 3107.5, 3110.0, 3112.5, 3115.0, 3117.5, 3120.0, 3122.5, 3125.0, 3127.5, 3130.0, 3132.5, 3135.0, 3137.5, 3140.0, 3142.5, 3145.0, 3147.5, 3150.0, 3152.5, 3155.0, 3157.5, 3160.0, 3162.5, 3165.0, 3167.5, 3170.0, 3172.5, 3175.0, 3177.5, 3180.0, 3182.5, 3185.0, 3187.5, 3190.0, 3192.5, 3195.0, 3197.5, 3200.0, 3202.5, 3205.0, 3207.5, 3210.0, 3212.5, 3215.0, 3217.5, 3220.0, 3222.5, 3225.0, 3227.5, 3230.0, 3232.5, 3235.0, 3237.5, 3240.0, 3242.5, 3245.0, 3247.5, 3250.0, 3252.5, 3255.0, 3257.5, 3260.0, 3262.5, 3265.0, 3267.5, 3270.0, 3272.5, 3275.0, 3277.5, 3280.0, 3282.5, 3285.0, 3287.5, 3290.0, 3292.5, 3295.0, 3297.5, 3300.0, 3302.5, 3305.0, 3307.5, 3310.0, 3312.5, 3315.0, 3317.5, 3320.0, 3322.5, 3325.0, 3327.5, 3330.0, 3332.5, 3335.0, 3337.5, 3340.0, 3342.5, 3345.0, 3347.5, 3350.0, 3352.5, 3355.0, 3357.5, 3360.0, 3362.5, 3365.0, 3367.5, 3370.0, 3372.5, 3375.0, 3377.5, 3380.0, 3382.5, 3385.0, 3387.5, 3390.0, 3392.5, 3395.0, 3397.5, 3400.0, 3402.5, 3405.0, 3407.5, 3410.0, 3412.5, 3415.0, 3417.5, 3420.0, 3422.5, 3425.0, 3427.5, 3430.0, 3432.5, 3435.0, 3437.5, 3440.0, 3442.5, 3445.0, 3447.5, 3450.0, 3452.5, 3455.0, 3457.5, 3460.0, 3462.5, 3465.0, 3467.5, 3470.0, 3472.5, 3475.0, 3477.5, 3480.0, 3482.5, 3485.0, 3487.5, 3490.0, 3492.5, 3495.0, 3497.5, 3500.0, 3502.5, 3505.0, 3507.5, 3510.0, 3512.5, 3515.0, 3517.5, 3520.0, 3522.5, 3525.0, 3527.5, 3530.0, 3532.5, 3535.0, 3537.5, 3540.0, 3542.5, 3545.0, 3547.5, 3550.0, 3552.5, 3555.0, 3557.5, 3560.0, 3562.5, 3565.0, 3567.5, 3570.0, 3572.5, 3575.0, 3577.5, 3580.0, 3582.5, 3585.0, 3587.5, 3590.0, 3592.5, 3595.0, 3597.5, 3600.0, 3602.5, 3605.0, 3607.5, 3610.0, 3612.5, 3615.0, 3617.5, 3620.0, 3622.5, 3625.0, 3627.5, 3630.0, 3632.5, 3635.0, 3637.5, 3640.0, 3642.5, 3645.0, 3647.5, 3650.0, 3652.5, 3655.0, 3657.5, 3660.0, 3662.5, 3665.0, 3667.5, 3670.0, 3672.5, 3675.0, 3677.5, 3680.0, 3682.5, 3685.0, 3687.5, 3690.0, 3692.5, 3695.0, 3697.5, 3700.0, 3702.5, 3705.0, 3707.5, 3710.0, 3712.5, 3715.0, 3717.5, 3720.0, 3722.5, 3725.0, 3727.5, 3730.0, 3732.5, 3735.0, 3737.5, 3740.0, 3742.5, 3745.0, 3747.5, 3750.0, 3752.5, 3755.0, 3757.5, 3760.0, 3762.5, 3765.0, 3767.5,

4H, Ar. H), 7.32 (m, 4H, Ar. ring), 9.77 (s, 1H, NH);  $^{13}\text{C}$  NMR ( $\delta$  ppm) (DMSO- $d_6$ ) 17.3, 17.3, 18.3, 35.2, 35.2, 42.3, 47.3, 47.8, 51.9, 119.2, 120.2, 125.2, 125.3, 125.3, 126.2, 126.6, 127.2, 127.3, 127.5, 128.3, 128.4, 171.3, 172.9; Mass (m/z) 367 (M+).

Dex 3: S(+) Methyl-2-(2-(4-isobutyl phenyl)propanamido)acetate—UV Spectra ( $\lambda_{\text{max}}$ ) in SGF 212 nm, in SIF 219 nm, in 80% human plasma 222 nm; IR (KBr,  $\text{cm}^{-1}$ ) 3280 (NH str. of amide), 3043 (aromatic CH str.), 2932 (C=O str. of ester), 1630 (C=N), 1290 (CO str. of ester);  $^1\text{H}$  NMR ( $\delta$  ppm) (DMSO- $d_6$ ) 1.38 (d,  $J = 6.7$  Hz, 6H,  $\text{CH}_3$ ), 2.42 (d,  $J = 7.3$  Hz, 2H,  $\text{CH}_2$ ), 3.80 (q,  $J = 7.1$  Hz, 1H, CH), 3.82 (q,  $J = 7.1$  Hz, 1H, CH), 7.48 (d,  $J = 8$  Hz, 4H, Ar.), 9.68 (s, 1H, NH);  $^{13}\text{C}$  NMR ( $\delta$  ppm) (DMSO- $d_6$ ) 17.3, 17.3, 17.8, 20.2, 35.2, 42.3, 47.8, 51.9, 63.2, 120, 120.8, 128.6, 128.9, 139.6, 172.9; Mass (m/z) 277 (M+).

Dex 4: S(+) Methyl 3-(4-hydroxyphenyl)-2-(2-(4-isobutylphenyl)propanamido)propanoate—UV Spectra ( $\lambda_{\text{max}}$ ) in SGF 208 nm, in SIF 221 nm, in 80 % human plasma 218 nm; IR (KBr,  $\text{cm}^{-1}$ ) 3362 (NH str. of amide), 3046 (aromatic CH str.), 1745 (C=O str. of ester), 1532 (C=N), 1280 (CO str. of ester);  $^1\text{H}$  NMR ( $\delta$  ppm) (DMSO- $d_6$ ) 1.28 (d,  $J = 6.7$  Hz, 6H,  $\text{CH}_3$ ), 3.62 (q,  $J = 7.1$  Hz, 1H, CH), 7.28 (d,  $J = 8$  Hz, 4H, Ar. ring), 7.63 (d,  $J = 8$  Hz, 4H, Ar. ring), 9.68 (s, 1H, NH);  $^{13}\text{C}$  NMR ( $\delta$  ppm) (DMSO- $d_6$ ) 17.8, 18.2, 18.3, 36.2, 47.3, 48.2, 48.3, 51.9, 120, 120.2, 120.6, 122, 122.2, 125, 125.6, 126, 126.2, 128.2, 128.4, 135.2, 171.2, 172.1; Mass (m/z) 383 (M+).

## Physicochemical characterization of the synthesized prodrugs

### Solubility

Approximately 5 mg of prodrug was dissolved in 5 mL of each solvent at  $37 \pm 1^\circ\text{C}$  in glass test tubes. The solvents used were 0.1 N NaOH, 0.1 N HCl, ethanol, methanol, ether, ethyl acetate, chloroform, acetone, DMF and water. Test tubes were gently shaken and solubility was observed. In case of any observed insoluble fractions, the

#### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings



7.4). It was tied at the opening end of dialysis tube; the dialysis tube containing (6%) egg albumin was dipped into the drug solution and covered. The whole assembly was placed on a magnetic stirrer and switched at low revolutions per minute. The temperature was maintained at  $37 \pm 0.5^{\circ}\text{C}$ . After every 1 h, 1 mL of the PBS containing drug solution was replaced with fresh 1 mL of PBS. Withdrawn sample was diluted further with 1 mL phosphate buffer and the concentration of prodrug was estimated using spectrophotometer at 223 nm. [Table 1](#) indicates the physicochemical properties of the synthesized prodrugs.

Table 1. Physicochemical properties of prodrugs.



[Download CSV](#) [Display Table](#)

### Hydrolysis rate determination in SGF and SIF<sup>9</sup>

In vitro hydrolysis studies of synthesized prodrugs were carried out in SGF at pH 1.2 (USP 1970) and SIF at pH 7.4 (USP 1970). A solution of 10 mg of prodrug was prepared in 90 mL of SIF (pH 7.4) or SGF (pH 1.2). An aliquot of 15 mL of this solution was withdrawn repeatedly and kept in test tubes maintained at  $37 \pm 0.5^{\circ}\text{C}$ . At a definite interval of time (0.5 h, 1–8 h), an aliquot was withdrawn from different test tubes and was transferred to micro-centrifuge tubes followed by addition of methanol to make up the volume. The tubes were placed in freezing mixture in order to arrest further hydrolysis, followed by vortexing at high speed for 5 min. After vortexing, the tubes were centrifuged at high speed (3000g) for 5 min. A 5 mL of clear supernatant obtained from each tube was measured on UV spectrophotometer for the amount of free Dex released after the hydrolysis of prodrugs in SGF and SIF at 210 nm. The kinetics of hydrolysis was monitored by increase in free drug concentration with time, and order of reaction was calculated using equation 1.

About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click “Settings”. For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings






A solution of 10 mg of prodrug was prepared in methanol (2 mL) and was added to 88 mL of 80% human plasma (pH 7.4 prepared by mixing 80 portion of plasma and 20 portion of phosphate buffer at pH 7.4). An aliquot of 15 mL of this solution was withdrawn and kept in test tubes maintained at  $37 \pm 0.5^\circ\text{C}$ . At definite interval of time (0–8 h), an aliquot of 22 mL was withdrawn and mixed with 0.5 %  $\text{ZnSO}_4$  solution. Samples were centrifuged at 6000g for 10 min and a clear supernatant solution was analyzed spectrophotometrically at 223 nm.

## Hydrolysis rate determination in rat faecal matter<sup>11</sup>

The prodrug was dissolved in phosphate buffer so that final concentration of the solution was 250  $\mu\text{g/mL}$ . Fresh faecal material of rats were weighed (about 1 g) and placed in different sets of test tubes. To each test tube, 2 mL of the prodrug solution was added and diluted to 5 mL with phosphate buffer. The sets of test tubes were incubated at  $37 \pm 0.5^\circ\text{C}$  for different intervals of time (0–8 h). For analysis, the free drug was extracted with 5 mL of methanol and estimated on UV spectrophotometer at 210 nm.

## Pharmacological evaluations

Dex and the synthesized prodrugs were evaluated for anti-inflammatory activity, analgesic activity, ulcerogenicity and histopathology, and a comparative study was performed. Test compounds and standard drugs were administered in the form of a suspension by oral route of administration for anti-inflammatory and analgesic studies (1% carboxymethylcellulose as a vehicle), as well as for ulcerogenicity studies (2% acacia as vehicle). Wistar albino rats of six groups, including a control and a standard group, each with six animals were selected. The selected animals were housed in acrylic cages at standard environmental conditions at  $25 \pm 2^\circ\text{C}$ , relative humidity of 45–55%, in a well-ventilated room maintained at 12:12 h light:dark cycle, fed with standard rodent diet and water *ad libitum*.



### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click “Settings”. For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings



The anti-inflammatory activity was determined by hind paw oedema method<sup>12</sup> using carrageenan as phlogistic agent. Wistar rats (100–200 g) were divided into six groups, each comprising of six rats, including a control and a standard group. The initial volume of right hind paw of rat was measured by plethysmometer without administration of the prodrug. A 1% sodium carboxymethylcellulose suspension containing a dose equivalent to the 2.4 mg or 12 mg kg<sup>-1</sup> body weight of Dex was administered orally. An equivalent quantity of prodrugs 4 mg of Dex-1, 4.36 mg of Dex-2, 3.52 mg of Dex-3 and 4.61 mg of Dex-4 were administered to the test groups. After 30 min of administration of the drugs, carrageenan (0.1 mL, 1% m/v) solution in normal saline was injected into the planter surface of right hind paw of each animal. The volume of right hind paw of albino rat was measured after 2, 4 and 6 h. The mean difference in the volume of the right hind paw of rats was compared with control and standard. The percent inhibition of paw oedema was calculated as

$$\text{Percent inhibition} = (1 - V_t/V_c) \times 100$$

where  $V_c$  is the mean relative change in paw edema volume in control group and  $V_t$  is the mean relative change in paw edema volume in test group.

## Analgesic activity

The analgesic activity was determined by thermal stimulus using tail flick method<sup>13</sup>. Analgesiometer was used for the determination of pain threshold of albino mice. Cold water was circulated through the water jackets of the instrument to avoid heating of the area around the hot wire. The rat (100–200 g) was placed in a holder through which the tail of the rat was protruded out. The reaction time was recorded at 1, 2, 3 and 4 h after the treatment and cutoff time was 9 s. The normal reaction time, i.e., the time taken to flick the tail was noted. Animals showing delayed response were rejected. The drug (dose equivalent to 2.4 mg or 12 mg kg<sup>-1</sup> body mass) was administered orally in

### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings



# Ulcerogenicity

GI toxicity of the synthesized prodrugs was measured and compared with the parent drug by measuring mean ulcer index (UI)<sup>14</sup>. The control group was administered orally in 2% acacia suspension. Test compounds and standard were administered orally (at 10 times higher dose) as a suspension in 2% acacia daily for 5 days. The rats (130–150 g) were fasted after the administration of last dose, thereafter they were killed by decapitation and the stomach was removed, opened and washed with distilled water. The lesions on the gastric mucosa were counted by visual examination using a binocular magnifier. Ulcers greater than 0.5 mm were recorded. The mean UI was calculated by severity of gastric mucosal lesions that are graded as (i) grade 1: >1 mm erosions (ii) grade 2: 1–2 mm erosions and (iii) grade 3: <2 mm erosions.

The UI was calculated as:

$$UI = [1 \times (\text{number of lesions of grade 1}) + 2 \times (\text{number of lesions of grade 2}) + 3 \times (\text{number of lesions of grade 3})]/10.$$

## Histopathological studies<sup>15</sup>

The histopathological studies of stomach of rats were carried out using haematoxylin and eosin stain at Pathology Department, Sri Venkateswara Veterinary University, Tirupati, India. The stomach tissues were removed from the rats and fixed in 10% normal saline for at least 48 h. These were then processed routinely and the tissues were embedded in paraffin wax. Histological sections were cut at 5–6  $\mu\text{m}$  and stained with routine haematoxylin and eosin. These were then examined by a consultant histopathologist. The lesions observed were assessed for the following mucosal atrophy, the presence of inflammatory cells in the wall, eosinophils, lymphocytes and plasma cells. Photomicrographs of representative lesions at various magnifications

### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click “Settings”. For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings



# Results and discussion

## Synthesis and characterization

This study describes the synthesis of amide prodrugs of Dex as Dex-1 {S(+) methyl-3-(1H-indol-3-yl)-2-(2-(4-isobutylphenyl)propanamido)propanoate}, Dex-2 {S(+) methyl 2-(2-(4-isobutylphenyl)propanamido)-3-phenylpropanoate}, Dex-3 {S(+) methyl-2-(2-(4-isobutyl phenyl)propanamido)acetate} and Dex-4 {S(+) methyl 3-(4-hydroxy phenyl)-2-(2-(4-isobutyl phenyl)propanamido)propanoate} as portrayed in [Scheme 1](#). The prodrugs were subjected to solubility, physicochemical characterization, protein binding and hydrolytic studies. All the prodrugs were observed to be highly soluble in organic solvents, sparingly soluble in alkaline solution and insoluble in acidic solutions. The high solubility of the prodrugs in organic solvents indicates their lipophilic behaviour. The physicochemical properties of synthesized prodrugs were determined, as well as the IR,  $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR and mass spectral analyses were carried out. The results of elemental analysis of synthesized prodrugs were in all case within  $\pm 0.4\%$  of theoretical value and were in confirmation of desired structure.

In vitro hydrolysis of Dex-1, Dex-2, Dex-3 and Dex-4 were carried out in SGF (pH 1.2), SIF (pH 7.4), 80% human plasma (pH 7.4) and rat faecal matter (pH 7.4) and their respective half life ( $t_{1/2}$ ) values in SIF were observed as 4.5, 4.8, 4.5 and 4.6 h, respectively. The comparative hydrolysis patterns of the synthesized prodrugs are depicted in [Figure 1](#). None of the prodrugs showed significant hydrolysis in SGF. The amount of Dex regenerated by hydrolysis of Dex-1, Dex-2, Dex-3 and Dex-4 in SIF was found as 71, 67, 76 and 73%, respectively, whereas 85, 82, 93 and 89%, respectively, in 80% human plasma and 86, 82, 93 and 89%, respectively, in rat faecal matter. The hydrolysis study revealed satisfactory hydrolysis of prodrugs in SIF and very

### About Cookies On This Site


We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings





Display full size

## Pharmacological studies

### Anti-inflammatory activity

Table 2 shows that after 6 h of administration of Dex, the percentage anti-inflammatory activity was found as 43.3%, whereas an improved value of 73.4, 77.3, 72.8 and 64.5% were observed for prodrugs Dex-1, Dex-2, Dex-3 and Dex-4, respectively. The maximum anti-inflammatory activity of prodrugs was observed at 6 h and remained practically constant upto 8 h. The anti-inflammatory activity of free Dex decreased with time, whereas that of its prodrugs increased with time due to its higher bioavailability compared with the parent drug. Statistical significant testing using one-way ANOVA showed that anti-inflammatory activity of Dex and its prodrugs were effective in comparison with control group. Thus, the amino acid prodrugs proved to be a suitable promoiety for Dex.

#### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings

Table of pro



Analge

In this article




The percentage protection in mice brought about by administration of drug is shown in Table 2. After 4 h of the administration of Dex, the percentage analgesia was observed as 46.4%, whereas for Dex-1, Dex-2, Dex-3 and Dex-4, corresponding values of 61.4, 59.7, 63.6 and 52.7% were observed. The study revealed that analgesic activity of Dex decreased with time, while the prodrugs showed an improved analgesic activity.

## Ulcerogenicity

Dex has produced a mean UI of 25.3 while that of its prodrugs resulted in producing very less values and is shown in Figure 2. The study revealed that the minimized side effect obtained in the prodrugs might be due to the inhibition of direct contact of carboxylic acid group of the drug to the gastric mucosa, which is mainly responsible for the damage.

Figure 2. Comparative ulcer index of dexibuprofen and its prodrugs.



Display full

### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings


The gastric group rats showed Dex group the basal

In this article



stomach lumen. In this zone, the structures of the gland were destroyed. They had disintegrated from the basal lamina and fallen into the lumen. The nuclei of these cells became smaller and dense, and their cytoplasms were stained as dark eosinophilic bodies. Small hemorrhagic areas and patches of inflammatory cell infiltrations were present in the lumen of the glands and lamina propria. Normal histological findings were displayed for Dex-1, Dex-2, Dex-3 and Dex-4 revealing that the prodrugs are not producing any ulceration in the gastric region.

Figure 3. Histopathological studies of dexibuprofen and its prodrugs on rat stomach.



Display full size

### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click “Settings”. For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings

Conclu

In the  
the struc  
studies o  
organic  
In this article

sized and  
rolysis  
bility in  
t faecal



quantitatively in 80% human plasma, rat faecal matter and SIF, but were resistant to hydrolysis at SGF indicating that the prodrugs are resistant to acidic conditions. In vivo studies showed sustained release of Dex upto 8 h as also evident from the longer anti-inflammatory activity observed with prodrugs treated animals compared with Dex-treated animals. The prodrugs were found to be significantly less ulcerogenic and with more analgesia than parent drug. The histopathological study revealed limited ulcer formation in stomach by the prodrugs. These findings suggested that the prodrugs are better in action as compared with dexibuprofen and are advantageous in having less GI side effects without loss of desired anti-inflammatory and analgesic activity of the drug.

## Acknowledgements

The authors thank M/s. Alkem Laboratories, Mumbai, India, for providing gift sample of dexibuprofen. The authors are grateful to Padmashree Dr. M. Mohan Babu, Chairman, Sree Vidyanikethan Educational Trust, Tirupati, India, for providing the necessary facilities to carry out this work.

## Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

## References

1. Kaehler ST, Phleps W, Hesse E. Dexibuprofen: pharmacology, therapeutic, use and safety

2. Ha...  
Me...  
Ds. Mini-Rev

### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings



3. Bajpai AK, Mishra A. Carboxymethyl cellulose (CMC) based semi-IPNs as carriers for controlled release of ciprofloxacin: an in-vitro dynamic study. J Mater Sci Mater Med 2008;19:2121–2130.

 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

4. Mishra A, Ravichandran V, Jain PK, Dixit VK, Agrawal RK. Synthesis, characterization and pharmacological evaluation of amide prodrugs of ketorolac. Europ J Med Chem 2008;43:2464–2472.

 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

5. Bhosle D, Bharambe S, Gairola N, Dhaneshwar SS. Mutual prodrug concept: fundamentals and applications. Indian J Pharm Sci 2006;68:286–294.

 | [Google Scholar](#)

6. Rasheed A, Kumar CKA. Novel approaches on prodrug based drug design, Pharm Chem J 2008;42:677–686

 | [Google Scholar](#)

7. Roy SD, Manoukian E. Permeability of ketorolac acid and its ester analogs (prodrug) through human cadaver skin. J Pharm Sci 1994;83:1548–1553.

 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

8. Idle JR, Millburn P, Williams RT. Taurine conjugates as metabolites of arylacetic acids in the ferret. Xenobiotica 1978;8:253–264.

 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

9. Nielsen J, et al. Synthesis and characterization of novel prodrugs of carboxylic acid and their pharmacological properties. J Pharm Sci 2008;97:1234–1245.

### About Cookies On This Site




We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click “Settings”. For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings

10. Mohan K, et al. Synthesis and characterization of novel prodrugs of ketorolac acid and their pharmacological properties. J Pharm Sci 2008;97:1234–1245.

1. Dev S, Deepali VM, Kadam SS, Dhaneshwar SR. Synthesis and pharmacological evaluation of cyclodextrin conjugate prodrug of Mefenamic acid. Indian J Pharm Sci 2007;69: 69–72.  
 | [Google Scholar](#)
2. Winter CA, Risely EA, Nuss GW. Carregeenan induced oedema in hind paw of the rat as assay for anti-inflammatory drugs. Proc Soc Exp Biol Med 1962;111:544–547.  
 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)
3. Kulkarni SK. Handbook of Experimental Pharmacology, 3rd ed., Vallabh Prakash, New Delhi, 2001;128–130.  
[Google Scholar](#)
4. Coili V, Putzolu S, Rossi V, Barcellona PS, Corradino C. The role of direct tissue contact in the production of gastrointestinal ulcers by anti-inflammatory drugs in rats. Toxicol Appl Pharmacol 1979;50:283–289.  
 | [PubMed](#) | [Google Scholar](#)
5. Yagmurca M, Ucar M, Fadillioglu E, Erdogan H, Ozturk F. The effects of nitric oxide on rat stomach injury induced by acetylsalicylic acid. Turk J Med Sci 2009; 39:13–19.  
[Web of Science ®](#) | [Google Scholar](#)

[Download PDF](#)

Related



### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click “Settings”. For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All 

Essential Only

Settings

## Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

## Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

## Open access


- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

## Help and information

- Help and contact
- Newsroom
- All journals
- Books


## Keep up to date

Register to receive personalised research and resources by email

 Sign me up



Copyright © 2024 [Informa UK Limited](#) [Privacy policy](#) [Cookies](#) [Terms & conditions](#)



[Accessibility](#)

Registered in England & Wales No. 3099067  
5 Howick Place | London | SW1P 1WG

### About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click “Settings”. For further information about the data we collect from you, please see our [Privacy Policy](#).

 Accept All

Essential Only

Settings